Wen Ching Hsu active positions
Companies | Position | Start | End |
---|---|---|---|
UWELL Biopharma, Inc.
UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | Director/Board Member | - | - |
Career history of Wen Ching Hsu
Statistics
International
Taiwan | 2 |
Operational
Director/Board Member | 1 |
Sectoral
Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
UWELL Biopharma, Inc.
UWELL Biopharma, Inc. Pharmaceuticals: MajorHealth Technology UWELL Biopharma, Inc. is a biotech company founded in 2003 and based in New Taipei, Taiwan. The Taiwanese company specializes in developing new cancer drugs using chimeric antigen receptor T-cell (CAR-T) technology. CAR-T therapy involves engineering a patient's T-cells to recognize and attack cancer cells. UWELL is currently conducting an open, single-center phase I clinical trial to evaluate the safety and efficacy of its anti-CD19 CAR-T cell injection in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. The study has been approved by the Institutional Review Board of Tri-Service General Hospital and the Ministry of Health and Welfare. UWELL has achieved success in treating adult blood cancer patients with CAR-T therapy, as evidenced by the clearance of cancer cells in the first case treated at Tri-Service General Hospital. | Health Technology |
- Stock Market
- Insiders
- Wen Ching Hsu
- Experience